Table S2.
Baseline demographic, clinical, and laboratory characteristics of unmatched patients in both groups.
| Characteristics | Non-CAKUT (n = 151) | CAKUT (n = 6) |
|---|---|---|
| Donor age (years), median (IQR) | 46.5 (34–53) | 42.5 (32.5–48.8) |
| Donor sex, % | ||
| Male | 56.3 | 50 |
| Female | 43.7 | 50 |
| Recipient sex, % | ||
| Male | 57.6 | 66.7 |
| Female | 42.4 | 33.3 |
| Recipient age (years), median (IQR) | 34 (26–45) | 30.5 (20.8–35) |
| Donor type, % | ||
| Living | 76.1 | 83.3 |
| Deceased | 23.8 | 16.6 |
| Follow-up duration (months), median (IQR) | 110 (80–159) | 29.5 (20.5–61.5) |
| HLA mismatches, % | ||
| ≤3 | 70.8 | 100 |
| >3 | 29.1 | 0 |
| Duration of dialysis (months), median (IQR) | 20 (6–48) | 207 (180–234) |
| Previous transplantation, % | 0.06 | 16.6 |
| PRA ≥30% before transplantation, % | 0.06 | 0 |
| Pretransplant KRT, % | ||
| No (Preemptive) | 15.9 | 0 |
| Yes (HD and/or PD) | 84.1 | 100 |
| Induction, % | ||
| No | 55.6 | 66.7 |
| Basiliximab | 19.9 | 16.6 |
| ATG | 24.5 | 16.6 |
| Immunosuppressive regimen, % | ||
| Tac/MPA/steroids | 43.7 | 66.7 |
| CsA/MPA/steroids | 19.2 | 0 |
| Tac/AZA/steroids | 8.6 | 16.6 |
| CsA/AZA/steroids | 2.6 | 0 |
| Others | 25.8 | 16.6 |
Abbreviations: ATG: anti-thymocyte globulin; AZA: azathioprine; CAKUT: congenital anomalies of the kidney and urinary tract; CsA: cyclosporine; HD: hemodialysis; HLA: human leukocyte antigen; IQR: interquartile range; KRT: kidney replacement therapy; MPA: mycophenolic acid; PD: peritoneal dialysis; Tac: tacrolimus.